# Targeting CDK7 in high-grade serous ovarian carcinoma

> **NIH NIH R01** · UNIVERSITY OF PENNSYLVANIA · 2022 · $434,368

## Abstract

PROJECT SUMMARY
Ovarian cancer remains the most lethal gynecologic malignancy and the fifth most frequent cause of cancer-
related mortality in women in the United States. Advanced-stage high-grade serous ovarian carcinoma (HGSOC)
is the most commonly diagnosed subtype and constitutes the majority of ovarian cancer deaths. Despite a high
response rate to initial platinum-taxane chemotherapy, patients with HGSOC frequently relapse and become
increasingly resistant to platinum analogues. PARP inhibitors have been recently approved to treat HGSOC;
however, the greatest clinical benefit from PARPi monotherapy has been mainly observed in tumors with
homologous recombination (HR) deficiency. Therefore, there is an urgent unmet medical need to develop
alternative therapeutic strategies for patients with HGSOC. Given that the transcriptional program is remarkably
dysregulated in cancer, resulting in cancer dependency on specific components of the transcriptional program
(termed “transcriptional addiction”), targeting transcriptional CDKs is emerging as a new strategy for cancer
treatment. Among the transcriptional CDKs, CDK7 shows the most significant copy number loss (dominantly
hemizygous) across multiple cancer types with the highest deletion score in HGSOC. Importantly, HGSOC cells
with hemizygous loss of CDK7 are highly sensitive to CDK7i treatment. Additionally, CDK7 loss is correlated with
increased sensitivities to DNA damaging drugs such as PARPi and platinum. Inhibition of CDK7 preferentially
represses the expression of genes in the DNA damage repair pathways and impairs the activity of HR. Therefore,
we hypothesize that hemizygous loss of CDK7 is a targetable vulnerability in HGSOC, and that CDK7i alone or
in combination with DNA damaging agents is a novel strategy to treat patients with HGSOC. Low-dose CDK7i
treatment can preferentially repress a group of HGSOC-associated genes that are driven by super enhancers,
serving as an effective and tolerable treatment for a select population of patients with HGSOC. The central goal
of this application is to study the mechanistic basis and translational potential of CDK7-targeted therapy in
HGSOC. We have assembled a team of collaborators with added expertise and resources to test the above
hypothesis through three specific aims. Specific Aim 1. Evaluate whether hemizygous loss of CDK7 is a
targetable vulnerability in HGSOC. Specific Aim 2. Characterize the molecular mechanisms of low-dose CDK7i
treatment in DNA damage response. Specific Aim 3. Evaluate CDK7i in combination with FDA-approved
therapies in preclinical models of HGSOC. Our proposed studies may provide strong rationale for clinical
development of CDK7 inhibitors for ovarian cancer treatment.

## Key facts

- **NIH application ID:** 10461935
- **Project number:** 5R01CA262070-02
- **Recipient organization:** UNIVERSITY OF PENNSYLVANIA
- **Principal Investigator:** Lin Zhang
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $434,368
- **Award type:** 5
- **Project period:** 2021-08-05 → 2026-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10461935

## Citation

> US National Institutes of Health, RePORTER application 10461935, Targeting CDK7 in high-grade serous ovarian carcinoma (5R01CA262070-02). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10461935. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*